Inhibrx, Inc. announced the appointment of David Matly, M.B.A., as Chief Commercial Officer and appointed Kristiina Vuori, M.D., Ph.D. to its Board of Directors, effective October 28, 2021. Dr. Vuori will serve as a member of the Audit Committee and Nominating and Governance Committee of the Board. In connection with this appointment, Inhibrx Chief Scientific Officer and Co-founder, Brendan Eckelman, Ph.D., stepped down from the Board. Mr. Matly brings extensive commercial launch and leadership experience across both orphan diseases and oncology. Mr. Matly joins from Novartis where he served as the global Vice President of the MDS/AML franchise. Since January 2010, Dr. Vuori has served as President of, and has held the Pauline and Stanley Foster Presidential Chair at, Sanford Burnham Prebys Medical Discovery Institute. Dr. Vuori has previously served or is currently serving on the Board of Directors of Bionano Genomics, Inc., Sio Gene Therapies, Forian, Inc., the American Association for Cancer Research, the California Institute for Regenerative Medicine, the California Breast Cancer Research Council and WebMD.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Companyâs clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.